EUVIMEDEUVIMED entdecken
Open Access

Tau positron emission tomography in preclinical Alzheimer’s disease

Philip S Insel iD, Christina B Young, Paul S Aisen, Keith A Johnson, Reisa A Sperling, Elizabeth C Mormino, Michael C Donohue

Brain · 13.02.2023 · 146 (2) · 700-711

DOI: 10.1093/brain/awac299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 13.08.2022. Verfasst von Philip S Insel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rates of tau accumulation in cognitively unimpaired older adults are subtle, with magnitude and spatial patterns varying in recent reports. Regional accumulation also likely varies in the degree to which accumulation is amyloid-β-dependent. Thus, there is a need to evaluate the pattern and consistency of tau accumulation across multiple cognitively unimpaired cohorts and how these patterns relate to amyloid burden, in order to design optimal tau end points for clinical trials. Using three large cohorts of cognitively unimpaired older adults, the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and companion study, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (n = 447), the Alzheimer’s Disease Neuroimaging Initiative (n = 420) and the Harvard Aging Brain Study (n = 190), we attempted to identify regions with high rates of tau accumulation and estimate how these rates evolve over a continuous spectrum of baseline amyloid deposition. Optimal combinations of regions, tailored to multiple ranges of baseline amyloid burden as hypothetical clinical trial inclusion criteria, were tested and validated. The inferior temporal cortex, fusiform gyrus and middle temporal cortex had the largest effect sizes of accumulation in both longitudinal cohorts when considered individually. When tau regions of interest were combined to find composite weights to maximize the effect size of tau change over time, both longitudinal studies exhibited a similar pattern—inferior temporal cortex, almost exclusively, was optimal for participants with mildly elevated amyloid β levels. For participants with highly elevated baseline amyloid β levels, combined optimal composite weights were 53% inferior temporal cortex, 31% amygdala and 16% fusiform. At mildly elevated levels of baseline amyloid β, a sample size of 200/group required a treatment effect of 0.40–0.45 (40–45% slowing of tau accumulation) to power an 18-month trial using the optimized composite. Neither a temporal lobe composite nor a global composite reached 80% power with 200/group with an effect size under 0.5. The focus of early tau accumulation on the medial temporal lobe has resulted from the observation that the entorhinal cortex is the initial site to show abnormal levels of tau with age. However, these abnormal levels do not appear to be the result of a high rate of accumulation in the short term, but possibly a more moderate rate occurring early with respect to age. While the entorhinal cortex plays a central role in the early appearance of tau, it may be the inferior temporal cortex that is the critical region for rapid tau accumulation in preclinical Alzheimer’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansAgedAmyloid beta-Peptidestau ProteinsPositron-Emission TomographyTemporal LobeBrainMagnetic Resonance Imaging

Stichwörter der Autor:innen

amyloid βclinical trialpreclinical Alzheimer’s diseasetau

Substanzen

Amyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
  • Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.
  • Department of Neurology, Harvard Aging Brain Study, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Philip S Insel

Förderung

  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Insel, P. S., Young, C. B., Aisen, P. S., Johnson, K. A., Sperling, R. A., Mormino, E. C., & Donohue, M. C. (2023). Tau positron emission tomography in preclinical Alzheimer’s disease. Brain, 146(2), 700-711. https://doi.org/10.1093/brain/awac299

Vancouver

Insel PS, Young CB, Aisen PS, Johnson KA, Sperling RA, Mormino EC, et al. Tau positron emission tomography in preclinical Alzheimer’s disease. Brain. 2023;146(2):700-711. doi:10.1093/brain/awac299

BibTeX
@article{Insel2023,
  author = {Insel, Philip S and Young, Christina B and Aisen, Paul S and Johnson, Keith A and Sperling, Reisa A and Mormino, Elizabeth C and Donohue, Michael C},
  title = {Tau positron emission tomography in preclinical Alzheimer’s disease},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {2},
  pages = {700--711},
  doi = {10.1093/brain/awac299}
}
Kostenlos starten →